Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis

類似資料

• P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE
  著者:: Maria Agustina Perusini, 等
  出版事項: (2023-08-01)
• The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report
  著者:: Yueru Ji, 等
  出版事項: (2024-07-01)
• Case report: Rechallenge with gilteritinib after acute pancreatitis in FLT3-positive AML
  著者:: Taner TAN, 等
  出版事項: (2025-01-01)
• Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase
  著者:: Maria Agustina Perusini, 等
  出版事項: (2024-12-01)
• Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML
  著者:: May Chiu, 等
  出版事項: (2024-10-01)